Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

37results about How to "Decrease the adverse events" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Use of spiro-oxindole compounds as therapeutic agents

ActiveUS8466188B2Improve effectivenessDecrease the adverse eventsBiocideNervous disorderMedicineEnantiomer

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and / or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.

Use of spiro-oxindole compounds as therapeutic agents

Use of spiro-oxindole compounds as therapeutic agents

Use of spiro-oxindole compounds as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions

InactiveUS20080194616A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerPyridine

This invention is directed to pyridopyrimidinone compounds of formula (I):wherein n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.

Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions

Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions

Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions

Owner:XENON PHARMACEUTICALS INC

Oxindole compounds and their uses as therapeutic agents

InactiveUS20070105820A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderOxindoleDisease cause

This invention is directed to oxindole compounds that are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.

Oxindole compounds and their uses as therapeutic agents

Oxindole compounds and their uses as therapeutic agents

Oxindole compounds and their uses as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Spiro-oxindole compounds and their uses as therapeutic agents

ActiveUS7700641B2Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseMedicine

This invention is directed to spiro-oxindole compounds of formula (I):wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Spiro-oxindole compounds and their uses as therapeutic agents

Spiro-oxindole compounds and their uses as therapeutic agents

Spiro-oxindole compounds and their uses as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Heterocyclic compounds and their uses as therapeutic agents

InactiveUS20080103151A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDisease causeStereochemistry

This invention is directed to heterocyclic compounds that are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.

Heterocyclic compounds and their uses as therapeutic agents

Heterocyclic compounds and their uses as therapeutic agents

Heterocyclic compounds and their uses as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Biaryl and biheteroaryl compounds useful in treating iron disorders

InactiveUS20080234384A1Improve effectivenessDecrease the adverse eventsBiocideOrganic chemistryArylEnantiomer

This invention is directed to compounds of formula (I):whereinm, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Biaryl and biheteroaryl compounds useful in treating iron disorders

Biaryl and biheteroaryl compounds useful in treating iron disorders

Biaryl and biheteroaryl compounds useful in treating iron disorders

Owner:XENON PHARMACEUTICALS INC

Dihydroindazole compounds useful in treating iron disorders

InactiveUS20080234327A1Improve effectivenessDecrease the adverse eventsBiocideOrganic chemistryEnantiomerIron disorder

This invention is directed to compounds of formula (I):whereinm, R1, R2, R3 and R4 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Dihydroindazole compounds useful in treating iron disorders

Dihydroindazole compounds useful in treating iron disorders

Dihydroindazole compounds useful in treating iron disorders

Owner:XENON PHARMACEUTICALS INC

Spiroheterocyclic compounds and their uses as therapeutic agents

InactiveUS20060252758A1Improve effectivenessDecrease the adverse eventsBiocideSenses disorderDiseaseEnantiomer

This invention is directed to spiroheterocyclic compounds of formula (I) wherein k, j, p, Q, R1, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.

Spiroheterocyclic compounds and their uses as therapeutic agents

Spiroheterocyclic compounds and their uses as therapeutic agents

Spiroheterocyclic compounds and their uses as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Spiroheterocyclic compounds and their uses as therapeutic agents

InactiveUS7799798B2Improve effectivenessDecrease the adverse eventsBiocideSenses disorderDiseaseEnantiomer

This invention is directed to spiroheterocyclic compounds of formula (I)whereink, j, p, Q, R1, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.

Spiroheterocyclic compounds and their uses as therapeutic agents

Spiroheterocyclic compounds and their uses as therapeutic agents

Spiroheterocyclic compounds and their uses as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Spiro-oxindole-derivatives as sodium channel blockers

InactiveUS20110269788A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerChannel blocker

This invention is directed to spiro-oxindole compounds of formulas (I), (II), (III), as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro-oxindole-derivatives as sodium channel blockers

Spiro-oxindole-derivatives as sodium channel blockers

Spiro-oxindole-derivatives as sodium channel blockers

Owner:XENON PHARMACEUTICALS INC

Biaryl ether sulfonamides and their use as therapeutic agents

InactiveUS20140256736A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEther

This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.

Biaryl ether sulfonamides and their use as therapeutic agents

Biaryl ether sulfonamides and their use as therapeutic agents

Biaryl ether sulfonamides and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

InactiveUS20110294842A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R1, R2a, R2b, R2c, R2d and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

Owner:XENON PHARMACEUTICALS INC

Spiro-oxindole compounds and their use as therapeutic agents

InactiveUS20100099728A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer

This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro-oxindole compounds and their use as therapeutic agents

Spiro-oxindole compounds and their use as therapeutic agents

Spiro-oxindole compounds and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

InactiveUS20100160291A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer

This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

InactiveUS20100160362A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R1, R2a, R2b, R2c, R2d and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

Owner:XENON PHARMACEUTICALS INC

Use of spiro-oxindole compounds as therapeutic agents

ActiveUS20100173967A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerMedicine

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and / or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.

Use of spiro-oxindole compounds as therapeutic agents

Use of spiro-oxindole compounds as therapeutic agents

Use of spiro-oxindole compounds as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Biaryl ether sulfonamides and their use as therapeutic agents

InactiveUS9481677B2Improve effectivenessDecrease the adverse eventsNervous disorderOrganic chemistryDiseasePharmaceutical medicine

This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.

Biaryl ether sulfonamides and their use as therapeutic agents

Biaryl ether sulfonamides and their use as therapeutic agents

Biaryl ether sulfonamides and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Spiro-oxindole compounds and their uses as therapeutic agents

ActiveUS20060252812A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Spiro-oxindole compounds and their uses as therapeutic agents

Spiro-oxindole compounds and their uses as therapeutic agents

Spiro-oxindole compounds and their uses as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Tricyclic compounds useful in treating iron disorders

InactiveUS20090069408A1Improve effectivenessDecrease the adverse eventsBiocideOrganic chemistryDiseaseEnantiomer

This invention is directed to, for example, compounds of formula (I):wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Tricyclic compounds useful in treating iron disorders

Tricyclic compounds useful in treating iron disorders

Tricyclic compounds useful in treating iron disorders

Owner:XENON PHARMACEUTICALS INC

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

InactiveUS20110237567A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer

This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Benzenesulfonamide compounds and their use as therapeutic agents

InactiveUS9630929B2Eliminate side effectsImprove effectivenessNervous disorderOrganic chemistryEnantiomerProdrug

This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Aromatic and heteroaromatic compounds useful in treating iron disorders

InactiveUS20100240713A1Improve effectivenessDecrease the adverse eventsBiocideHalogenated hydrocarbon active ingredientsEnantiomerIron disorder

This invention is directed to compounds of formula (I), wherein m, formula (II), R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Aromatic and heteroaromatic compounds useful in treating iron disorders

Aromatic and heteroaromatic compounds useful in treating iron disorders

Aromatic and heteroaromatic compounds useful in treating iron disorders

Owner:XENON PHARMACEUTICALS INC

Benzenesulfonamide compounds and their use as therapeutic agents

ActiveUS10246453B2Improve effectivenessDecrease the adverse eventsOrganic active ingredientsNervous disorderEnantiomerProdrug

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Use of spiro-oxindole compounds as therapeutic agents

ActiveUS20110172282A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerMedicine

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and / or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.

Use of spiro-oxindole compounds as therapeutic agents

Use of spiro-oxindole compounds as therapeutic agents

Use of spiro-oxindole compounds as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Spiro-oxindole compounds and their use as therapeutic agents

InactiveUS20110112162A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer

This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro-oxindole compounds and their use as therapeutic agents

Spiro-oxindole compounds and their use as therapeutic agents

Spiro-oxindole compounds and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Benzenesulfonamide compounds and their use as therapeutic agents

InactiveUS20140296245A1Improve effectivenessEliminate side effectsBiocideNervous disorderDiseaseEnantiomer

This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

ActiveUS20200071313A1Increased potencyEliminate side effectsNervous disorderOrganic chemistrySulfonilamideDisease

This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Owner:XENON PHARMACEUTICALS INC

Benzenesulfonamide compounds and their use as therapeutic agents

ActiveUS10745392B2Eliminate side effectsUseful in treatmentOrganic active ingredientsNervous disorderDiseasePharmaceutical medicine

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and / or epileptic seizure disorders.

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Benzenesulfonamide compounds and their use as therapeutic agents

ActiveUS10815229B1Improve effectivenessDecrease the adverse eventsOrganic active ingredientsNervous disorderDiseaseProdrug

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compounds and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

ActiveUS20200157089A1Eliminate side effectsUseful in treatmentOrganic active ingredientsNervous disorderDiseaseAryl

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and / or epileptic seizure disorders.

Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

Owner:XENON PHARMACEUTICALS INC

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Patsnap Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Patsnap Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com